Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V114 versus Prevnar 13 in healthy infants
2016-001117-25Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2017
- Modality
- Vaccines & Immunotherapeutics, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of pneumococcal 15-valent conjugate vaccine and Prevnar 13 in pneumococcal disease (3 arms), sponsored by Merck & Co. Primary endpoint: Proportion of subjects meeting serotype-specific IgG threshold after dose 3. Started Mar 2017; status: completed.
02
Drugs
pneumococcal 15-valent conjugate vaccinePrevnar 13
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on 2016-001117-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001117-25.